(BFM Stock Exchange) – The Danish laboratory has announced positive results for early phase clinical trials evaluating new anti -obesity treatment, Amycretine.

Dethered by LVMH, last week, the Novo Nordisk pharmaceutical group is expected to regain its first place in European capitalization this Friday, January 24.

If LVMH wins 1.46%, the Danish company jumped 7.3% in Copenhagen, towards the end of the session. Novo Nordisk currently displays a market capitalization (the value of all shares) of 371 billion euros against 365.6 billion euros for the number one luxury.

Novo Nordisk is carried out by the announcement of favorable results for early clinical trials (phase 1b/2A). In this case these trials evaluated Amycretine, a potential new generation treatment of society against overweight and obesity. The company intends to both develop this medication to administer it by subcutaneous and oral route.

As part of the trial in question, patients had received an administration by subcutaneous medication on a weekly rate.

Significant weight loss

Novo Nordisk has announced that people treated as part of these clinical trials (125 in total) had displayed an average weight loss of 16.2% over 28 weeks and 22% over 36 weeks against respective figures of 2.3% and 2% for patients treated with placebo.

“We are very encouraged by the results of phase 1B/2A of the subcutaneous study on Amycretine in people with overweight or obesity” said Martin Lange, executive vice-president responsible for development at Novo Nordisk, quoted in a press release.

“Based on these results, Novo Nordisk now plans to continue the clinical development of Amycretine in adults with overweight or obesity,” said Novo Nordisk.

This announcement allows Novo Nordisk to recover from Applomb, while the group had disappointed the market last December.

On December 20, the action had unscrewed by 20.7%, following disappointing results on a phase III clinical trial (the last step before the potential marketing of a drug).

This clinical trial focused on Cagrisama, a new anti-obesity treatment of the Danish group. The results of this trial had shown that 22.7% of patients treated with Cagrisema had significant weight loss after 68 weeks, rate that fell to 20.4% including patients who abandoned the treatment during road.

These figures were disappointing because the company was targeting a rate of more than 25%. In addition, this rate only showed a modest improvement compared to the Zepbound of the American competitor Eli Lilly, another anti-obsity medication. The Zepbound had displayed a significant weight loss rate over a comparable period of approximately 20%, according to Barclays.

The announcement of Friday on Amycretine “finally breaks the wave of negative feelings with regard to Novo,” told Bloomberg Emily Field, a Barclays analyst based in London. The data is “up to the best” results obtained so far at this stage for injections against weight loss, she added.

In September, UBS estimated the peak of sales at $ 5 billion for Amycretine, only in its oral version.